A key development element for new molecular format biological products is to leverage the appropriate analytical tools to enhance product and process understanding throughout the development lifecycle. Here, Lonza experts highlight the benefits of using mass spectrometry technologies to accelerate and de-risk product and process development.
You may also be interested in:
Parenteral Drug Product
Bispecific Antibody
Analytical Development
Author(s):
Qifeng Zhang
Global Senior Technical Lead
Ian Anderson
Global Senior Principal Scientist, Global Analytical Development
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.
Latest briefing from the Knowledge Center
Webinar (on-demand)
Simplifying ADC Development: An Integrated Path from Concept to Commercialization
As the Antibody-Drug Conjugate (ADC) market continues to expand, developers face increasing...
CDMO Notes Blog post
Making More from Every Bioreactor with Lonza’s OptiALTO™ Intensified Fed-Batch Platform
Lonza’s OptiALTO™ intensified fed-batch platform offers a practical way to increase productivity...
Article
De-risking Biologic Drug Development: Strategic Solutions for Biotech Companies
Biotech companies face unique challenges in developing increasingly complex biologic therapies. How...
Article
Scaling Biologics with Early De-risking Package: Integrated Developability and Expression Q&A
Discover how integrated in silico tools, CHO expression, and in vitro immunogenicity testing help...
Article
Optimizing Lentiviral Vector Development For In Vivo Delivery Of Cell and Gene Therapies
Challenges and emerging solutions in developing and manufacturing lentiviral vectors for in vivo...
Webinar (on-demand)
Integrated ADC Offering: From Concept to Commercialization
Antibody-drug conjugates (ADCs) are transforming targeted therapies. However, their structural...
Article
The IND Advantage: Why Early De-Risking Is a Strategic Imperative for Complex Biologics
As biologics grow more complex, early identification and the mitigation of manufacturability,...
Blog
Inhalable mRNA lipid nanoparticle powders via spray drying: is it possible?
Dry powder inhaled formulations of small molecule drugs are a mainstay of treatment for respiratory...
Webinar (on-demand)
Cracking Complexity: Learnings from 70+ Bispecific Antibody Programs
The biologics pipeline is becoming increasingly complex as next generation antibody formats,...
Webinar (on-demand)
Accelerating Success: Advanced Developability Strategies for Bioconjugates ​and ADCs
In this on-demand webinar, our experts explore how Lonza’s Early Development Services support...
Webinar (on-demand)
The 24 Months Before CGT Launch
Every second counts: what real cell and gene therapy launches teach us For cell and gene...
Peer-reviewed publication
Antibody–Drug Conjugates Drug Product Formulation and Process Development, Scalability and Stability...
Antibody–drug conjugates (ADCs) combine the target specificity of monoclonal antibodies with the...